David vs. Goliath: Taiwan’s PGI Wins $23M Settlement in Sequencing Patent Dispute with U.S. PacBio

In a recent resolution for the genomic sequencing industry, Pacific Biosciences (PacBio) of California and Personal Genomics of Taiwan (PGI) have officially settled their long-standing patent infringement litigation. The settlement, disclosed in recent SEC filings, ends nearly seven years of legal battles across multiple continents, with PacBio agreeing to pay a minimum of $23 million through 2029. At the center of the dispute was U.S. Patent No. 7,767,441, which PGI alleged was infringed by PacBio’s single-molecule sequencing technology used in its Sequel and Sequel II platforms—a molecular detection approach that courts ultimately determined remained protected under PGI’s patent. The case has drawn attention as a rare example of a smaller research-driven biotechnology firm successfully defending its intellectual property against a far larger publicly traded sequencing company.

The Terms of the Settlement

The agreement, finalized on March 5, 2026, establishes a structured payment plan and provides PacBio with legal certainty regarding its core technology. Key highlights include:

• Fixed Payments: PacBio (PACB) will pay PGI an initial $8 million in the first quarter of 2026, followed by $5 million annually in 2027, 2028, and 2029.
• Revenue Performance Milestones: The 2027 payment could increase by up to $2 million ($1 million if 2026 revenue hits $165M, and another $1 million if it reaches $180M).
• Licensing & Immunity: PacBio receives a worldwide, royalty-free, non-exclusive license to U.S. Patent No. 7,767,441 and its related patent family.
• Covenant Not to Sue: A five-and-a-half-year agreement prevents further litigation between the parties and binds PGI’s successors and transferees.

Origins of the Dispute

The legal friction began in 2019 when PGI, a spin-off from Taiwan’s Industrial Technology Research Institute (ITRI) founded by Dr. Johnsee Lee, filed suit in Delaware. PGI is a biotechnology company focused on single-molecule sequencing technologies and related intellectual property. PGI alleged that PacBio’s flagship Sequel and Sequel II  sequencing instruments infringed on their ‘441 patent. Public filings indicate that PacBio and PGI discussed potential licensing arrangements as early as 2010 before negotiations ultimately stalled. At its core, the case centered on whether PacBio’s sequencing systems relied on technology protected by PGI’s patent.

The Technology at the Center of the Case

The ‘441 patent is critical because it describes an apparatus for identifying a single biomolecule using sensors placed in extremely close proximity to the molecule being sequenced—a cornerstone of the “long-read” sequencing technology that PacBio popularized. In this case, the patent describes detection architectures closely related to zero-mode waveguides (ZMWs), nanophotonic structures that enable real-time observation of DNA polymerase activity at the single-molecule level. ZMWs form the technological foundation of PacBio’s Single Molecule Real-Time (SMRT) sequencing platform.

For PGI, this dispute was a validation of its role as a specialized technology developer. Unlike PacBio, which built an expansive commercial platform, PGI’s leverage is rooted in its patent portfolio and its origins within Taiwan’s semiconductor and biosensing ecosystem. Its approach reflects Taiwan’s broader strengths in nanoscale sensor engineering and optoelectronic technologies, traditionally associated with the semiconductor industry but increasingly applied to genomics. 

During the PTAB proceedings and subsequent Federal Circuit review, courts determined that while several claims could be invalidated, the core claims describing this detection architecture remained valid. In simple terms, the courts concluded that while some parts of the patent could be removed, the core invention—detecting individual biomolecules using closely positioned sensors—remained valid. This preserved PGI’s ability to enforce the patent, giving the smaller Taiwanese firm significant legal leverage despite its comparatively limited commercial footprint in the sequencing market.

A See-Saw Legal Battle

Before reaching this $23 million conclusion, the case saw several dramatic turns:

1. Patent Challenges: PacBio attempted to invalidate the ‘441 patent through the U.S. Patent Trial and Appeal Board (PTAB). In 2022, the PTAB invalidated 17 claims but upheld 25 key claims.
2. Appeals Court Affirmation: In January 2024, the U.S. Court of Appeals for the Federal Circuit affirmed the PTAB’s ruling, maintaining PGI’s victory. The ’441 patent was originally filed in 2008 and issued in 2010, placing its expected expiration toward the end of the decade. As a result, the settlement effectively secures PacBio’s freedom to operate during the remaining commercially significant years of the patent’s enforceable life.
3. International Pressure: Beyond the U.S. courts, PGI had also initiated legal proceedings against PacBio in China, significantly increasing the operational risk for the California-based firm.

Despite PacBio’s efforts to invalidate the patent, PGI continued to defend the remaining claims through multiple legal venues, illustrating how smaller technology developers increasingly rely on intellectual property enforcement to compete in capital-intensive biotechnology markets.

Timeline of the PacBio–PGI Patent Dispute

Industry Impact & Outlook

For PGI, the settlement represents a validation of the company’s intellectual property strategy, demonstrating that early-stage sequencing innovations developed outside major commercial platforms can still shape the competitive dynamics of the global genomics industry. At the same time, the settlement allows PacBio to clear its balance sheet of “uncertain litigation outcomes” at a time when competition in the sequencing market is intensifying.

Beyond the financial outcome, the agreement represents more than a financial settlement—it reinforces the strategic value of its intellectual property portfolio. The company has positioned itself as a specialized technology developer focused on single-molecule biosensing architectures rather than a full commercial sequencing platform. By successfully defending the core claims of the ’441 patent through multiple legal venues, PGI demonstrated that foundational innovations developed within Taiwan’s research ecosystem can exert meaningful influence over global genomics technologies.

Equity and litigation analysts remain neutral on the news, suggesting that while the $23 million is a substantial cost, the multi-year legal certainty provides a necessary foundation for PacBio’s future growth objectives. While $23 million represents a meaningful settlement, it remains relatively modest compared with PacBio’s annual revenue, reported at $160 million in 2025. This financial stability is further bolstered by the $48.1 million in net cash generated from the 2025 sale of its short-read sequencing assets, which effectively pre-funded these legal obligations and extended the company’s liquidity.

Technical Precision and Industry Inference

The technical core of the upheld ‘441 patent focuses on a specific, high-stakes capability: the “single biomolecule” identification. The court affirmed that PGI’s patent describes an apparatus capable of identifying a molecule by examining that individual unit alone—strictly excluding older technologies that require amplification or “ensemble” copies. This precise architectural distinction is what gave the smaller Taiwanese firm its definitive edge; it proved that PGI held the blueprint for the most advanced high-fidelity sequencing methods.

For PacBio, this technical reality made the settlement a necessity. Their signature HiFi sequencing approach—which repeatedly sequences circularized DNA templates to reach accuracy levels exceeding 99.9%—relies directly on the single-molecule detection principles validated in PGI’s patent. By resolving this, PacBio “buys” a clean legal runway to compete against Oxford Nanopore and Illumina’s 2026 long-read push. The $23 million agreement allows PacBio to shift its focus toward achieving positive cash flow by the end of 2026, leveraging its 2025 asset sales to navigate an increasingly aggressive market. This move suggests an industry-wide trend toward intellectual property consolidation to avoid the “patent thickets” that once slowed the short-read sequencing era, allowing firms to focus instead on the aggressive price wars and AI-driven analytics currently shaping 2026’s genomic landscape.

Ultimately, this resolution serves as a significant narrative shift in the genomics industry. It marks a clear “David vs. Goliath” victory, where a specialized technology developer successfully leveraged its intellectual property to command multi-year payments from a global market leader. The outcome underscores a new industry reality: in the race for genomic precision, the foundational IP of smaller, research-driven innovators like PGI can play a more decisive role in shaping the field than the sheer commercial scale of the industry’s giants.

Author

Bernice Lottering